Join the Hadlima group to help and get support from people like you.
Hadlima News
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon Hadlima (adalimumab-bwwd) Injection
INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE) May 27, 2025 – Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has...
Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease
FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
INCHEON, Korea – July 24, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (ad...
Further information
Related condition support groups
Ankylosing Spondylitis, Crohn's Disease - Maintenance, Crohn's Disease, Crohn's Disease - Acute, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis